Estrogen Quickly Reduces Lipoprotein (a) - One Of The "Bad Cholesterols" - But "How" Remains A Mystery

September 11, 1997

DALLAS, Sept. 23 -- Estrogen replacement therapy used to help relieve menopausal symptoms quickly reduces the amount of lipoprotein (a), one of the "bad cholesterols" in the blood, say researchers reporting in this month's American Heart Association's journal Arteriosclerosis, Thrombosis and Vascular Biology.

Estrogen replacement taken orally reduces the amount of Lp (a) within a week, and the maximum effect was seen after three weeks. The estrogen also increases the amount of high-density lipoprotein (HDL), the so-called "good cholesterol," say researchers at the Columbia University College of Physicians and Surgeons in New York.

The method of reducing this form of cholesterol differs physiologically from reduction of other low-density lipoproteins (LDLs) but the researchers aren't sure why, notes Lars Berglund, M.D.., co-author of the study.

If scientists can understand the process it would help them design drugs to reduce the risk of heart disease by reducing the Lp (a) without notable side effects. Anabolic steroids reduce Lp (a), but these can have serious adverse reactions. A possible therapy available now is niacin, but niacin also has problems with side effects in some individuals.

Estrogen taken in low doses eases the physical problems associated with menopause, including osteoporosis, a condition in which bones become porous and brittle. The therapy remains somewhat controversial because higher doses have been linked with endometrial cancer.

"Lp (a) is a form of cholesterol influenced by genetics," Berglund says. Levels are stable over time within individuals, although they can vary greatly from one person to another. The stability is an advantage in studying the protein because the natural level acts as a baseline for tests and the effects of any drug are easier to see.

Earlier tests using estrogen on men suffering from advanced prostate cancer showed a dramatic 50 percent reduction in Lp (a) when they took estrogen as treatment.

In the Columbia study, 15 healthy, post-menopausal women with an average age of 55 were given either four weeks of estrogen replacement therapy or a placebo in a randomized double-blind study. After the initial cycle, the dosages were reversed: the women who had the estrogen received the placebo and the other women the estrogen. Within one week the amount of Lp (a) in the blood of 14 of the 15 women was significantly reduced with the estrogen pills. The reduction continued until the third week when it leveled off.

There were no adverse effects from the estrogen replacement therapy, the article stated.

The Lp (a) finally was reduced by an average of 23 percent. The women represented three racial or ethnic groups and although the number of subjects was too small to test for differences among them, the effects appeared to be equal for all the women.

The effectiveness of estrogen on the other forms of cholesterol was different, Berglund says. Reductions didn't happen as quickly, hinting that they were subjected to different mechanisms.

"Further studies are warranted to elucidate the mechanisms behind the estrogen-induced changes," the report concludes.

The other two authors of the paper were Catherine H. Tuck, MD. and Stephen Holleran.
-end-
Media Advisory: Dr. Berglund can be reached at (212) 305-2068.

Reporters may call (214) 706-1396 for copies of his journal report. (Please do not publish telephone numbers.)

American Heart Association

Related Cholesterol Articles from Brightsurf:

Cholesterol's effects on cellular membranes
The findings have far-reaching implications in the general understanding of disease, the design of drug delivery methods, and many other biological applications that require specific assumptions about the role of cholesterol in cell membranes.

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

Microbes might manage your cholesterol
Researchers discover a link between human blood cholesterol levels and a gene in the microbiome that could one day help people manage their cholesterol through diet, probiotics, or entirely new types of treatment.

Experimental cholesterol-lowering drug effective at lowering bad cholesterol, study shows
Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov.

Rethinking how cholesterol is integrated into cells
Cholesterol is best known in connection with cardiovascular disease, but cholesterol is also vital for many fundamental processes in the body.

Seed oils are best for LDL cholesterol
Using a statistical technique called network meta-analysis, researchers have combined the results of dozens of studies of dietary oils to identify those with the best effect on patients' LDL cholesterol and other blood lipids.

Cholesterol leash: Key tethering protein found to transport cellular cholesterol
Cholesterol is an essential component of living organisms, but the mechanisms that transport cholesterol inside the cell are poorly understood.

New way to treat cholesterol may be on the horizon
A breakthrough discovery by scientists at Houston Methodist Research Institute could change the way we treat cholesterol.

How low should LDL cholesterol go?
New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events.

Does boosting 'good' cholesterol really improve your health?
A new review addresses the mysteries behind 'good' HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients.

Read More: Cholesterol News and Cholesterol Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.